PGR and neoplasm: We assessed the association of TAP1 and TAP2 levels with tumor grade and other clinicopathologic features such as stage, HER2/neu status, and estrogen receptor (ER) and progesterone receptor (PR) expression levels in an attempt to identify the relationship between loss of expression and aggressive tumor behavior.